CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors
Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.
Related Articles
FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer
FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer.
Registration
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
Payment stability bill introduced, would reverse 2025 cuts – American Society for Radiation Oncology (ASTRO)
Legislators introduced a Medicare payment stability bill that would reverse 2025 cuts
Men face substantial lifelong risk of oral HPV infection
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, a study provides information on…
AI Improves Mammography Tumor Detection
A study of more than 460,000 women shows that AI assistance can help radiologists spot nearly 18% more breast tumors on mammograms. The study also…
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients…
Editors’ Selections from Relevant Scientific Publications
Immune Response Pathways in FAP during cancer formation (by Esplin et al. via Nat Cancer)Multi-omic analysis of colon tissue specimens from people with familial adenomatous…
Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis
The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
PURPOSETo assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs)…
How to prioritize between oxygen and iron
In this issue of Blood, Zhang et al introduce a new dimension to the intricate interplay between sensing mechanisms for oxygen and iron. They show how…
